Inozyme PharmaINZY
INZY
About: Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.
Employees: 67
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
1,200% more call options, than puts
Call options by funds: $13K | Put options by funds: $1K
7% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 28
0% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]
8% less funds holding
Funds holding: 105 [Q4 2024] → 97 (-8) [Q1 2025]
8.83% less ownership
Funds ownership: 81.56% [Q4 2024] → 72.73% (-8.83%) [Q1 2025]
35% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 20
71% less capital invested
Capital invested by funds: $145M [Q4 2024] → $42.5M (-$103M) [Q1 2025]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$4
0%
upside
Avg. target
$9
126%
upside
High target
$16
301%
upside
4 analyst ratings
1 positive
25%
3 neutral
75%
0 negative
0%
Wells Fargo Tiago Fauth | 0%upside $4 | Equal-Weight Downgraded | 16 May 2025 |
Jefferies Ryan Deschner | 0%upside $4 | Hold Downgraded | 16 May 2025 |
Needham Joseph Stringer | 201%upside $12 | Hold Downgraded | 16 May 2025 |
HC Wainwright & Co. Edward White | 301%upside $16 | Buy Reiterated | 10 Apr 2025 |
Financial journalist opinion
Based on 7 articles about INZY published over the past 30 days
Neutral
Business Wire
3 weeks ago
INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inozyme Pharma, Inc. (NasdaqGS: INZY) to BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN). Under the terms of the proposed transaction, shareholders of Inozyme will receive $4.00 in cash for each share of Inozyme that they own. KSF is seeking to determine whether this consideration and the process that.
Neutral
PRNewsWire
4 weeks ago
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Inozyme Pharma, Inc. - INZY
NEW YORK , May 16, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Inozyme Pharma, Inc. (NASDAQ: INZY ), relating to the proposed merger with BioMarin Pharmaceutical Inc. Under the terms of the agreement, BioMarin will commence a cash tender offer to acquire all of the outstanding shares of Inozyme common stock at a price of $4.00 per share.
Neutral
PRNewsWire
4 weeks ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHTR and INZY on Behalf of Shareholders
NEW YORK , May 16, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Charter Communications, Inc. (NASDAQ: CHTR)'s merger with Cox Communications. If you are a Charter shareholder, click here to learn more about your legal rights and options.
Neutral
Business Wire
4 weeks ago
INZY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inozyme Pharma, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Inozyme Pharma, Inc. (NASDAQ: INZY) to BioMarin Pharmaceutical Inc. for $4.00 per share is fair to Inozyme shareholders. Halper Sadeh encourages Inozyme shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Inozyme a.
Positive
Investors Business Daily
4 weeks ago
How BioMarin's $270 Million Takeover Led This Dollar Stock To A Triple-Digit Gain
BioMarin said Friday it would spend $270 million to acquire Inozyme Pharma, sending shares of the latter skyrocketing by triple digits.
Neutral
Business Wire
4 weeks ago
Shareholder Alert: The Ademi Firm investigates whether Inozyme Pharma, Inc. is obtaining a Fair Price for its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Inozyme (Nasdaq: INZY) for possible breaches of fiduciary duty and other violations of law in its transaction with BioMarin. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of Inozyme will receive $4.00 per share in an all-cash transaction for a total consideration.
Neutral
PRNewsWire
4 weeks ago
BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma
Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Children Expected in Early 2026 with Potential Launch in 2027; Additional Clinical Programs to Expand to Patients of all Ages Potential First-in-Disease Treatment for ENPP1 Deficiency Conference Call and Webcast Scheduled Today at 8:45 a.m. ET SAN RAFAEL, Calif.
Neutral
GlobeNewsWire
1 month ago
Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights
- Interim data from ENERGY 3 trial highlight INZ-701's potential to modify disease course in ENPP1 Deficiency, with sustained phosphate increases and favorable safety and immunogenicity profile to date - - ENERGY 3 trial on track for topline data in first quarter of 2026; no patient dropouts, dose adjustments or discontinuations, and no new safety signals - - Petra Duda, M.D., Ph.D. appointed Chief Medical Officer - BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today reported financial results for the first quarter ended March 31, 2025, and provided business highlights.
Neutral
GlobeNewsWire
2 months ago
Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency
- Data from the largest retrospective analysis of ENPP1 Deficiency provides insights into the evolution of the disease's serious cardiovascular and musculoskeletal complications - - Findings highlight the urgent need for early and improved diagnosis, care and treatments that address the long-term systemic effects of ENPP1 Deficiency - BOSTON, April 10, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced the publication of a paper titled, “Phenotypic characterization of ENPP1 deficiency: generalized arterial calcification of infancy and autosomal recessive hypophosphatemic rickets type 2” in JBMR Plus that characterizes the severity and progression of ENPP1 Deficiency. Inozyme collaborated with leading disease experts Carlos Ferreira, M.D.
Neutral
GlobeNewsWire
2 months ago
Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference
BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Doug Treco, Ph.D., CEO and Chairman of Inozyme, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, from 2:15-2:55pm ET.
Charts implemented using Lightweight Charts™